July 2024

First Allogeneic T-Cell Therapy BLA Filing acceptance by U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would be the First Approved Therapy in U.S. for EBV+ PTLD and will be commercialized in the US by the n

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: